1. Yao Q, Frank M, Glynn M, et al. Rheumatic manifestations in HIV-1 infected in-patients and literature review. Clin Exp Rheumatol 2008; 26(5): 799–806.
2. Nguyen BY, Reveille JD. Rheumatic manifestations associated with HIV in the highly active antiretroviral therapy era. Curr Opin Rheumatol 2009; 21(4): 404–410.
3. Walker-Bone K, Doherty E, Sanyal K, Churchill D. Assessment and management of musculoskeletal disorders among patients living with HIV. Rheumatology (Oxford) 2017; 56(10): 1648–1661.
4. Boyd MA, Boffito M, Castagna A, et al. Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps. HIV Med 2019; 20(Suppl 1): 3–11.
5. Worobey M, Telfer P, Souquière S, et al. Island biogeography reveals the deep history of SIV. Science 2010; 329: 1487.
6. Keele BF, Van Heuverswyn F, Li Y, et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006; 313: 523.
7. Murphey-Corb M, Martin LN, Rangan SR, et al. Isolation of an HTLV-III-related retrovirus from macaques with simian AIDS and its possible origin in asymptomatic mangabeys. Nature 1986; 321: 435.
8. Beyrer C. HIV epidemiology update and transmission factors: risks and risk contexts – 16th International AIDS Conference epidemiology plenary. Clin Infect Dis 2007; 44: 981.
9. Marešová M. Zpráva o výskytu a šíření HIV/AIDS za rok 2018. [online] http://www.szu.cz/tema/ prevence/zpravaovyskytuasirenihivaidszarok2018
10. Arasteh K, Des Jarlais DC. Injecting drug use, HIV, and what to do about it. Lancet 2008; 372: 1709.
11. Branson BM, Stekler JD. Detection of acute HIV infection: we can’t close the window. J Infect Dis 2012; 205: 521.
12. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunologic classification of HIV-related disease in adults and children. Geneva, Switzerland: World Health Organization 2007; 1–48.
13. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global AIDS update 2017. http: //www.unaids.org/sites/default/files/media_asset/20170720_Data_book_2017_en.pdf
14. Sedaghat AR, Rastegar DA, O’Connell KA, et al. T cell dynamics and the response to HAART in a cohort of HIV-1-infected elite suppressors. Clin Infect Dis 2009; 49: 1763.
15. Zákoucká H. Národní referenční laboratoř pro HIV/AIDS. http://www.szu.cz/ narodnireferencnilaboratorproaids
16. Lawson E, Sabin C, Perry N, Richardson D, et al. Is HIV painful? An epidemiologic study of the prevalence and risk factors for pain in HIV-Infected patients. Clin J Pain 2015; 31(9): 813–819.
17. Parker R, Stein DJ, Jelsma J. Pain in people living with HIV/AIDS: a systematic review. J Int AIDS Soc 2014; 17(1): 18719.
18. Muñoz Fernández S, Cardenal A, Balsa A, et al. Rheumatic manifestations in 556 patients with human immunodeficiency virus infection. Sem Arth Rheum 1991; 21: 30–39.
19. Hochberg MC, Fox R, Nelson KE, et al. HIV infection is not associated with Reiter’s syndrome: data from the Johns Hopkins Multicenter AIDS cohort study. AIDS 1990; 4: 1149–1151.
20. Berman A, Espinoza LR, Diaz JD, et al. Rheumatic manifestations of Human Immunodeficiency Virus infection. Am J Med 1988; 85: 59–64.
21. Marquez J, Restrepo CS, Candia L, et al. Human immunodeficiency virus-associated rheumatic disorders in the HAART era. J Rheumatol 2004; 31: 741–746.
22. Ouédraogo DD, Ntsiba H, et al. Clinical spectrum of rheumatologic diseases in a department of rheumatology in Ouagadougou (Burkina Faso). Clin Rheumatol 2014; 33(3): 385–389.
23. Keruly JC, Chaisson RE, Moore RD. Increasing incidence of avascular necrosis of the hip in HIV-infected patients. J Acquir Immune Defic Syndr 2001; 28: 101–102.
24. Miller KD, Masur H, Jones EC, et al. High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med 2002; 137(1): 17.
25. Goh SSL, Lai PSM, Tan ATB, et al. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors. Osteoporos Int 2018; 29(3): 595–613.
26. Dao CN, Patel P, Overton ET, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011; 52: 396.
27. Berman A, Robredo G, Spindler A, et al. Rheumatic manifestations in populations at risk for HIV infection: the added effect of HIV. J Rheumatol 1991; 18: 1564–1567.
28. Cuellar ML, Espinoza LR. Rheumatic manifestations of HIV-AIDS. Baillieres Best Pract Res Clin Rheumatol 2000; 14: 579.
29. Stein CM, Davis P. Arthritis associated with HIV infection in Zimbabwe. J Rheumatol 1996; 23: 506.
30. Ekwom PE, Oyoo GO, Amayo EO, Muriithi IM. Prevalence and characteristics of articular manifestations in human immunodeficiency virus infection. East Afr Med J 2010; 87(10): 408–414.
31. Duvic M, Johnson TM, Rapini RP, et al. Acquired immunodeficiency syndrome-associated psoriasis and Reiter’s syndrome. Arch Derm 1987; 123: 1622–1632.
32. Yao Q, Frank M, Glynn M, Altman RD. Rheumatic manifestations in HIV-1 infected in-patients and literature review. Clin Exp Rheumatol 2008; 26(5): 799–806.
33. Reveille JD, Conant MA, Duvic M. Human immunodeficiency virus-associated psoriasis, psoriatic arthritis, and Reiter’s syndrome: a disease continuum? Arthritis Rheum 1990; 33(10): 1574.
34. Njobvu P, McGill P. Soft tissue rheumatic lesions and HIV infection in Zambians. J Rheumatol 2006; 33: 2493–2497.
35. Bijlsma JWJ, Derksen RHWM, Huber-Brunning O, Borleffs JCC. Does AIDS ‚cure‘ rheumatoid arthritis? Ann Rheum Dis 1988; 47: 350–351.
36. Siva C, Brasington RD. Worsening of arthritis with antiretroviral therapy: the coexistence of rheumatoid arthritis and human immunodeficiency virus infection revisited. J Clin Rheum 2001; 7: 42–46.
37. Du Toit R, Whitelaw D, Taljaard JJ, et al. Lack of specificity of anti-cyclic citrullinated peptide antibodies in advanced human immunodeficiency virus infection. J Rheumatol 2011; 38(6):
38. Mehsen-Cêtre N, Cazanave C. Osteoarticular manifestations associated with HIV infection. Joint Bone Spine 2017; 84(1): 29–33.
39. Nicholson P, Saunsbury E, D’Angelo S, et al. Prevalence of and risk factors for gout in HIV-positive adults: a case-control study. Int J STD AIDS. doi:10.1177/0956462418799803 [Epub ahead of print].
40. Silverberg MJ, Jacobson LP, French A, et al. Age and racial/ethnic differences in the prevalence of reported symptoms in HIV-infected persons on antiretroviral therapy. J Pain Symptom Manage 2009; 38: 197–207.
41. Chiowchanwisawakit P, Koolvisoot A, Ratanasuwan W, Suwanagool S. Prevalence of rheumatic disease in HIV-infected Thai patients. J Med Assoc Thailand 2005; 88: 1775–1781.
42. Kole AK, Roy R, Kole DC. Musculoskeletal and rheumatological disorders in HIV infection: Experience in a tertiary referral center. Indian J Sex Transm Dis 2013; 34(2): 107–112.
43. Schnitzler LJ, Schreckenbach T, Nadaj-Pakleza A, et al. Sporadic late-onset nemaline myopathy: clinico-pathological characteristics and review of 76 cases. Orphanet J Rare Dis 2017; 12(1): 86.
44. Noe MM, Jain AG, Shahi d S, Majeed U. severe rhabdomyolysis as an unusual presentation of primary human immunodeficiency virus infection. Cureus 2018; 10(7): e3041.
45. Lloyd TE, Pinal-Fernandez I, Michelle EH, et al. Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. Neurology 2017; 88(15): 1454–1460.
46. Virot E, Duclos A, Adelaide L, et al. Autoimmune diseases and HIV infection: a cross-sectional study. Medicine (Baltimore) 2017; 96(4): e5769.
47. Robinson-Papp J, Simpson DM. Neuromuscular diseases associated with HIV-1 infection. Muscle Nerve 2009; 40: 1043–1053.
48. Johnson RW, Williams FM, Kazi S, et al. Human immunodeficiency virus-associated polymyositis: a longitudinal study of
outcome. Arthritis Rheum 2003; 49: 172–178.
49. Sagar A, Mohanty AP, Bahal A. Zidovudine-induced myopathy: A study in Indian patients. J Neurosci Rural Pract 2010; 1(2): 63–66.
50. Cupler EJ, Danon MJ, Jay C, et al. Early features of zidovudine-associated myopathy: histopathological findings and clinical correlations. Acta Neuropathol (Berl) 1995; 90: 1–6.
51. Daikh BE, Holyst MM. Lupus-specific autoantibodies in concomitant human immunodeficiency virus and systemic lupus erythematosus: case report and literature review. Semin Arth Rheum 2001; 30(6): 418–425.
52. Colon M, Martińez DE. Clinical remission of systemic lupus erythematosus after human immunodeficiency virus infection. P R Health Sci J 2007; 26(1): 79–81.
53. Haas M, Kaul S, Eustace JA. HIV-associated immune complex glomerulonephritis with ‚lupus-like‘ features: a clinicopathologic study of 14 cases. Kidney Int 2005; 67(4): 1381–1390.
54. Jakez-Ocampo J, Carrillo-Maravilla E, Richaud-Patin Y, et al. An unusual multiplex systemic lupus erythematosus family with high prevalence of nephropathy, late-onset disease, and one member with disease-onset post-HIV therapy. J Clin Rheumatol 2008; 14(1): 34–37.
55. Chetty R. Vasculitides associated with HIV infection. J Clin Pathol 2001; 54(4): 275–278.
56. Chetty R, Batitang S, Nair R. Large artery vasculopathy in HIV-positive patients: another vasculitic enigma. Hum Pathol 2000; 31(3): 374–379.
57. Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 1994; 120: 932.
58. Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis 2014; 58: e1.
59. Djawe K, Buchacz K, Hsu L, et al. Mortality risk after AIDS-defining opportunistic illness among HIV-infected persons – San Francisco, 1981–2012. J Infect Dis 2015; 212: 1366.
60. Basu D, Williams F, Ahn C, Reveille J. Changing spectrum of the diffuse infiltrative lymphocytosis syndrome. Arth Rheum 2006; 55(3): 466–472.
61. Kazi S, Cohen PR, Williams F, et al. The diffuse infiltrative lymphocytosis syndrome. Clinical and immunogenetic features in 35 patients. AIDS 1996; 10(4): 385–391.
62. De Silva DJ, Obi AA, Mitchell SM. Bilateral panuveitis in HIV-1-infected patients with CD8 lymphocytosis. Ocul Immunol Inflamm 2005; 13(4): 311–316.
63. Lawson E, Bond K, Churchill D, Walker-Bone K. A case of immune reconstitution syndrome: adult-onset still’s disease in a patient with HIV infection. Rheumatology 2009; 48: 446–447.
64. Fournier A, Martin-Blondel G, Lechapt-Zalcman E, et al. Immune reconstitution inflammatory syndrome unmasking or worsening AIDS-related progressive multifocal leukoencephalopathy: a literature review. Front Immunol 2017; 8: 577.
65. Fox C, Walker-Bone K. Evolving spectrum of HIV-associated rheumatic syndromes. Best Pract Res Clin Rheumatol 2015; 29(2): 244–258.
66. Foisy MM, Yakiwchuk EM, Chiu I, Singh AE. Adrenal suppression and Cushing’s syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med 2008; 9(6): 389–396.
67. Piconi S, Parisotto S, Rizzardini G, et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 2011; 118(12): 3263–3272.
68. Chiang G, Sassaroli M, Louie M, et al. Inhibition of HIV-1 replication by hydroxychloroquine. Clin Ther 1996; 18(6): 1080–1092.
69. Njobvu PD, McGill PE. Sulphasalazine in the treatment of HIV-related spondyloarthropathy. Br J Rheumatol 1997; 36(3): 403–404.
70. Carroll MB, Fields JH, Clerc PG. Rheumatoid arthritis in patients with HIV: management challenges. Open Access Rheumatol 2016; 8: 51–59.
71. Menon K, Van Voorhees AS, Bebo BF, Jr, et al. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2010; 62(2): 291–299.
72. Read SW, DeGrezia M, Ciccone EJ, et al. The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants. PLoS One 2010; 5(8): e11937.
73. Schlapfer E, Fischer M, Ott P, Speck RF. Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea. AIDS 2003; 17: 1613–1620.
74. Chamberlain FE, Dinani N, Gurmit K, et al. Azathioprine can be safely used in HIV-infected patients. AIDS 2014; 28: 447–448.
75. Sellam J, Bouvard B, Masson C, et al. Use of infliximab to treat psoriatic arthritis in HIV-positive patients. Joint Bone Spine 2007; 74(2): 197–200.
76. Cepeda EJ, Williams FM, Ishimori ML, et al. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008; 67(5): 710–712.